Loading…
Loading…
Could you please provide some more details on that, the opportunity to improve upon the profile of J&J's bravado
could you please discuss the outlook for accelerating growth as Humira's absolute dollar declines diminish in coming years
could you please discuss your vision for leveraging your global aesthetics commercial footprint to sell obesity drugs in the future
the industry is facing three major US Government risks, actions that are harming biopharma innovation, including actions significant FDA disruption
could you please frame your long-term commercial vision for this candidate, including what some may underappreciate about how broadly it could potentially be adopted
Could you please discuss your agenda for M&A, including the potential to leverage your franchise strength in related product categories
I was just hoping that you could maybe just call out the top two or three pipeline cards that are turning over that could be most impactful for Amgen
can you please discuss how you see the potential for IV biosimilars to compete with hyaluronidase subcutaneous versions which are set to experience significant uptake ahead of the opportunity to la...
could you just explain why you're announcing today the plans to initiate a new olpasiran Phase III trial in high-risk patients when it's not going to be initiated until late '25 or early '26?
how you plan to position it relative to TREMFYA given the similar indications
my understanding is that coverage has been pretty flat on a net basis over the last 18 months
I'm hoping that you can comment, Dave, on discussions with the Trump administration on tariffs outside of the 232 investigation
I was just hoping you could clarify the comment earlier. I think there was a comment about additional PBM coverage coming in March
I wanted to just pivot to the long-acting relaxin candidate VOLENRELAXIN. And so the company had advanced it into a CKD trial in the fourth quarter